Eli Lilly and Company has agreed to acquire Kelonia Therapeutics for up to $7 billion, expanding its oncology pipeline with experimental in vivo CAR-T therapies. The acquisition, announced on April 20, includes a $3.25 billion upfront payment, with the remainder contingent on clinical, regulatory, and commercial milestones. The transaction is expected to close in the second half of 2026.
Core Facts & Immediate Action
Eli Lilly will integrate Kelonia’s lead program, KLN-1010, which targets cancerous myeloma plasma cells. Unlike traditional ex vivo CAR-T therapies, Kelonia’s approach reprograms T-cells directly inside the body via intravenous delivery, eliminating the need for cell extraction and lab engineering. Jacob Van Naarden, Lilly’s president of oncology, called the data "nothing short of remarkable," emphasizing the therapy’s potential to broaden access beyond specialized medical centers.
Deeper Dive & Context
Therapeutic Innovation
Kelonia’s in vivo CAR-T technology represents a shift from current ex vivo methods, which require harvesting, modifying, and reintroducing a patient’s T-cells. The intravenous approach simplifies treatment by bypassing preconditioning and lab processing, potentially reducing costs and expanding accessibility. Johnson & Johnson’s Carvykti, a CAR-T treatment for multiple myeloma, generated $1.89 billion in sales last year, highlighting the market’s demand for advanced therapies. Gilead’s recent acquisition of Arcellx for $7.8 billion underscores the competitive landscape in CAR-T development.
Market Implications
Lilly’s acquisition positions it as a major player in hematology, complementing its existing oncology portfolio. Van Naarden noted the strategic advantage of offering a therapy that doesn’t rely on academic medical centers, which are currently the primary providers of ex vivo CAR-T treatments. The deal reflects a broader industry trend toward in vivo solutions, which could lower barriers to treatment and improve patient outcomes.
Financial & Regulatory Considerations
The $7 billion deal includes performance-based payments, aligning Lilly’s financial commitment with Kelonia’s ability to meet clinical and regulatory milestones. This structure mitigates risk while incentivizing rapid development. The transaction is subject to customary closing conditions and is expected to finalize in late 2026.
Competitive Landscape
Kelonia’s technology competes with established CAR-T therapies like Carvykti and anito-cel (Arcellx’s rival to Carvykti). The acquisition signals Lilly’s intent to challenge industry leaders in the rapidly evolving CAR-T space, where innovation and scalability are critical.